JP2022523301A5 - - Google Patents
Info
- Publication number
- JP2022523301A5 JP2022523301A5 JP2021543226A JP2021543226A JP2022523301A5 JP 2022523301 A5 JP2022523301 A5 JP 2022523301A5 JP 2021543226 A JP2021543226 A JP 2021543226A JP 2021543226 A JP2021543226 A JP 2021543226A JP 2022523301 A5 JP2022523301 A5 JP 2022523301A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- nucleic acid
- angptl7
- position corresponding
- acid molecule
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024213170A JP2025023307A (ja) | 2019-01-23 | 2024-12-06 | アンジオポエチン様7(angptl7)阻害剤による眼疾患の治療 |
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962795665P | 2019-01-23 | 2019-01-23 | |
| US62/795,665 | 2019-01-23 | ||
| US201962880609P | 2019-07-30 | 2019-07-30 | |
| US62/880,609 | 2019-07-30 | ||
| US201962902683P | 2019-09-19 | 2019-09-19 | |
| US62/902,683 | 2019-09-19 | ||
| US201962909573P | 2019-10-02 | 2019-10-02 | |
| US62/909,573 | 2019-10-02 | ||
| PCT/US2020/014373 WO2020154268A2 (en) | 2019-01-23 | 2020-01-21 | Treatment of ophthalmic conditions with angiopoietin-like 7 (angptl7) inhibitors |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024213170A Division JP2025023307A (ja) | 2019-01-23 | 2024-12-06 | アンジオポエチン様7(angptl7)阻害剤による眼疾患の治療 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022523301A JP2022523301A (ja) | 2022-04-22 |
| JP2022523301A5 true JP2022523301A5 (cg-RX-API-DMAC7.html) | 2023-01-30 |
Family
ID=69591771
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021543226A Pending JP2022523301A (ja) | 2019-01-23 | 2020-01-21 | アンジオポエチン様7(angptl7)阻害剤による眼疾患の治療 |
| JP2024213170A Pending JP2025023307A (ja) | 2019-01-23 | 2024-12-06 | アンジオポエチン様7(angptl7)阻害剤による眼疾患の治療 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024213170A Pending JP2025023307A (ja) | 2019-01-23 | 2024-12-06 | アンジオポエチン様7(angptl7)阻害剤による眼疾患の治療 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US11767526B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3914711A2 (cg-RX-API-DMAC7.html) |
| JP (2) | JP2022523301A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20210132045A (cg-RX-API-DMAC7.html) |
| CN (1) | CN113646432A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2020210630C1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3126476A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL284700B2 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2021008797A (cg-RX-API-DMAC7.html) |
| SG (1) | SG11202107497XA (cg-RX-API-DMAC7.html) |
| WO (1) | WO2020154268A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11845989B2 (en) | 2019-01-23 | 2023-12-19 | Regeneron Pharmaceuticals, Inc. | Treatment of ophthalmic conditions with angiopoietin-like 7 (ANGPTL7) inhibitors |
| CA3126476A1 (en) | 2019-01-23 | 2020-07-30 | Regeneron Pharmaceuticals, Inc. | Treatment of ophthalmic conditions with angiopoietin-like 7 (angptl7) inhibitors |
| JP2022535717A (ja) | 2019-05-24 | 2022-08-10 | エンピリコ インク. | アンジオポエチン様7(angptl7)関連疾患の処置 |
| WO2022072356A1 (en) * | 2020-09-29 | 2022-04-07 | Empirico Inc. | Compositions and methods for the treatment of angiopoietin like 7 (angptl7) related diseases |
| WO2022115383A1 (en) * | 2020-11-24 | 2022-06-02 | Empirico Inc. | Treatment of sos2 related diseases and disorders |
| WO2022182768A1 (en) * | 2021-02-26 | 2022-09-01 | Regeneron Pharmaceuticals, Inc. | Treatment of inflammation with glucocorticoids and angiopoietin-like 7 (angptl7) inhibitors |
| CN116997653A (zh) * | 2021-02-26 | 2023-11-03 | 雷杰纳荣制药公司 | 用糖皮质激素和血管生成素样7(angptl7)抑制剂治疗炎症 |
| KR20240099232A9 (ko) * | 2021-09-30 | 2025-12-10 | 리제너론 파마슈티칼스 인코포레이티드 | Rho 구아닌 뉴클레오타이드 교환 인자 12[Rho Guanine Nucleotide Exchange Factor 12, ARHGEF12] 억제제를 이용한 녹내장 치료 |
| JP2024538646A (ja) * | 2021-10-01 | 2024-10-23 | アルナイラム ファーマシューティカルズ, インコーポレイテッド | ANGPTL7を標的化するためのiRNA組成物および方法 |
| EP4453210A1 (en) * | 2021-12-22 | 2024-10-30 | Regeneron Pharmaceuticals, Inc. | Treatment of kidney diseases with angiopoietin like 3 (angptl3) inhibitors |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1781787T3 (en) | 2004-08-23 | 2017-07-31 | Sylentis Sau | TREATMENT OF EYE DISORDERS FEATURED BY AN INCREASED INTRAOCULAR PRESSURE WITH SIRNAS |
| EP2035576A4 (en) | 2006-07-05 | 2010-09-08 | Orientbio Co Ltd | METHOD OF CANCER DIAGNOSIS BY DETERMINING THE METHYLATION OF TRANSITION ZONES |
| CN102481269B (zh) | 2009-05-11 | 2015-10-07 | 博格有限责任公司 | 包含辅酶q10的药物组合物及其制备方法 |
| US8642737B2 (en) | 2010-07-26 | 2014-02-04 | Baxter International Inc. | Nucleophilic catalysts for oxime linkage |
| EP3081233B1 (en) | 2009-07-27 | 2020-12-23 | Baxalta GmbH | Glycopolysialylation of proteins other than blood coagulation proteins |
| US8809501B2 (en) | 2009-07-27 | 2014-08-19 | Baxter International Inc. | Nucleophilic catalysts for oxime linkage |
| BR112012001814A8 (pt) | 2009-07-27 | 2018-02-06 | Baxalta GmbH | Conjugados de proteína de coagulação sanguínea |
| RU2744370C2 (ru) | 2009-07-27 | 2021-03-05 | Баксалта Инкорпорейтед | Конъюгаты белков свертывания крови |
| WO2011051276A1 (en) | 2009-10-26 | 2011-05-05 | Externautics S.P.A. | Colon and rectal tumor markers and methods of use thereof |
| US9551034B2 (en) | 2010-01-11 | 2017-01-24 | Genomic Health, Inc. | Method to use gene expression to determine likelihood of clinical outcome of renal cancer |
| EP2397559A1 (en) | 2010-06-17 | 2011-12-21 | Max-Delbrück-Centrum Für Molekulare Medizin | Stage-specific biomarkers for the diagnosis of acute kidney injury |
| US20120010230A1 (en) | 2010-07-08 | 2012-01-12 | Macdougall John R | Methods and compositions for identification, assessment and treatment of cancers associated with hedgehog signaling |
| TWI534152B (zh) | 2010-07-30 | 2016-05-21 | 巴克斯特國際公司 | 用於肟連接的親核性催化劑 |
| ES2800983T3 (es) | 2010-12-22 | 2021-01-07 | Baxalta GmbH | Materiales y métodos para conjugar un derivado de ácido graso soluble en agua con una proteína |
| PL2710375T3 (pl) | 2011-05-18 | 2019-07-31 | Baxalta GmbH | Testy aktywności zależne od modyfikacji |
| AU2012328524B2 (en) | 2011-10-28 | 2017-05-18 | Excelse Bio, Inc. | Protein formulations containing amino acids |
| WO2013120497A1 (en) | 2012-02-15 | 2013-08-22 | Curevac Gmbh | Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein |
| AU2013204754C1 (en) | 2012-05-16 | 2018-10-11 | Takeda Pharmaceutical Company Limited | Nucleophilic Catalysts for Oxime Linkage |
| US20130310546A1 (en) | 2012-05-16 | 2013-11-21 | Bater Healthcare Sa | Nucleophilic catalysts for oxime linkage and use of nmr analyses of the same |
| US20150174203A1 (en) | 2012-05-30 | 2015-06-25 | Icahn School Of Medicine At Mount Sinai | Compositions And Methods For Modulating Pro-Inflammatory Immune Response |
| CA2884455A1 (en) | 2012-09-21 | 2014-03-27 | Integragen | A new method for classification of liver samples and diagnosis of focal nodule dysplasia, hepatocellular adenoma, and hepatocellular carcinoma |
| US9206423B2 (en) * | 2012-12-30 | 2015-12-08 | The Regents Of The University Of California | Methods of modulating compliance of the trabecular meshwork |
| WO2014167529A1 (en) | 2013-04-10 | 2014-10-16 | Institut De Cardiologie De Montreal | Methods and compositions for preventing and treating atherosclerosis |
| WO2015132303A1 (en) * | 2014-03-04 | 2015-09-11 | Sylentis Sau | Sirnas and their use in methods and compositions for the treatment and/or prevention of eye conditions |
| WO2015179633A1 (en) | 2014-05-22 | 2015-11-26 | Fred Hutchinson Cancer Research Center | Lilrb2 and notch-mediated expansion of hematopoietic precursor cells |
| CA3005980A1 (en) | 2015-11-24 | 2017-06-01 | Commonwealth Scientific And Industrial Research Organisation | Production of viruses in avian eggs |
| CN108603188A (zh) | 2015-11-24 | 2018-09-28 | 联邦科学技术研究组织 | 在细胞培养物中产生病毒 |
| CA3019635A1 (en) | 2016-03-31 | 2017-10-05 | Baylor Research Institute | Angiopoietin-like protein 8 (angptl8) |
| JP7050215B2 (ja) | 2016-08-19 | 2022-04-08 | ツールゲン インコーポレイテッド | 人工的に操作された血管新生調節系 |
| SG10201913074WA (en) * | 2016-08-30 | 2020-03-30 | Regeneron Pharma | Methods of treating severe insulin resistance by interfering with glucagon receptor signaling |
| US12447213B2 (en) | 2016-10-07 | 2025-10-21 | The Broad Institute, Inc. | Modulation of novel immune checkpoint targets |
| AU2017357072A1 (en) | 2016-11-14 | 2019-05-30 | Memorial Sloan-Kettering Cancer Center | Stem cell derived schwann cells |
| WO2018174861A1 (en) | 2017-03-21 | 2018-09-27 | Mprobe Inc. | Methods and compositions for detecting early stage breast cancer with rna-seq expression profiling |
| EP3600108A4 (en) | 2017-03-23 | 2021-01-06 | The Regents of the University of California | STIMULATION OF HAIR GROWTH BY SENESCENCE CELLS AND SENESCENCE-ASSOCIATED SECRETORIC PHENOTYPE |
| JP2018164442A (ja) * | 2017-03-28 | 2018-10-25 | 国立大学法人 熊本大学 | 皮膚有棘細胞癌の判定、予防又は治療方法 |
| JP6779164B2 (ja) * | 2017-03-28 | 2020-11-04 | ヤンマーパワーテクノロジー株式会社 | 作業車両の自律走行システム |
| JP7493940B2 (ja) | 2017-05-31 | 2024-06-03 | コモンウェルス サイエンティフィック アンド インダストリアル リサーチ オーガナイゼーション | 鳥類における形質選択 |
| EP3737666A4 (en) | 2018-01-12 | 2022-01-05 | Kymera Therapeutics, Inc. | PROTEIN DEGRADATION AGENTS AND ASSOCIATED USES |
| EP3740224A4 (en) | 2018-01-18 | 2022-05-04 | Adanate, Inc. | ANTI-LILRB ANTIBODIES AND THEIR USES |
| GB201806118D0 (en) | 2018-04-13 | 2018-05-30 | Univ Edinburgh | Macrophage use |
| CA3126476A1 (en) | 2019-01-23 | 2020-07-30 | Regeneron Pharmaceuticals, Inc. | Treatment of ophthalmic conditions with angiopoietin-like 7 (angptl7) inhibitors |
| JP2022535717A (ja) | 2019-05-24 | 2022-08-10 | エンピリコ インク. | アンジオポエチン様7(angptl7)関連疾患の処置 |
| WO2022072356A1 (en) | 2020-09-29 | 2022-04-07 | Empirico Inc. | Compositions and methods for the treatment of angiopoietin like 7 (angptl7) related diseases |
-
2020
- 2020-01-21 CA CA3126476A patent/CA3126476A1/en active Pending
- 2020-01-21 WO PCT/US2020/014373 patent/WO2020154268A2/en not_active Ceased
- 2020-01-21 SG SG11202107497XA patent/SG11202107497XA/en unknown
- 2020-01-21 CN CN202080022870.2A patent/CN113646432A/zh active Pending
- 2020-01-21 AU AU2020210630A patent/AU2020210630C1/en active Active
- 2020-01-21 IL IL284700A patent/IL284700B2/en unknown
- 2020-01-21 KR KR1020217026590A patent/KR20210132045A/ko not_active Ceased
- 2020-01-21 US US16/748,006 patent/US11767526B2/en active Active
- 2020-01-21 EP EP20705596.3A patent/EP3914711A2/en active Pending
- 2020-01-21 JP JP2021543226A patent/JP2022523301A/ja active Pending
- 2020-01-21 MX MX2021008797A patent/MX2021008797A/es unknown
-
2021
- 2021-05-12 US US17/318,023 patent/US11512309B2/en active Active
-
2024
- 2024-12-06 JP JP2024213170A patent/JP2025023307A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008520242A5 (cg-RX-API-DMAC7.html) | ||
| US20100119474A1 (en) | Chronic obstructive pulmonary disease susceptibility and related compositions and methods | |
| JP2002272489A5 (cg-RX-API-DMAC7.html) | ||
| JP2023531935A5 (cg-RX-API-DMAC7.html) | ||
| JP2006521812A (ja) | 慢性関節リウマチに関連する遺伝的多型、その検出方法および使用 | |
| Greber-Platzer et al. | Evidence against the current hypothesis of “gene dosage effects” of trisomy 21: ets-2, encoded on chromosome 21” is not overexpressed in hearts of patients with Down syndrome | |
| JP2001333785A (ja) | MxAタンパク質の多型遺伝子およびその使用 | |
| JP2024521754A5 (cg-RX-API-DMAC7.html) | ||
| JP2022525545A5 (cg-RX-API-DMAC7.html) | ||
| JP2022515838A5 (cg-RX-API-DMAC7.html) | ||
| JP2022525456A5 (cg-RX-API-DMAC7.html) | ||
| JP4398379B2 (ja) | B型肝炎ウイルスの薬物抵抗性を識別する方法 | |
| JP2005507654A5 (cg-RX-API-DMAC7.html) | ||
| JP4242590B2 (ja) | 慢性関節リウマチの疾患感受性遺伝子、及びその利用 | |
| JP2022525546A5 (cg-RX-API-DMAC7.html) | ||
| JP2022544393A (ja) | マクロファージ刺激1受容体(mst1r)バリアント及びその使用 | |
| JP4145129B2 (ja) | Pcrクランピング法 | |
| RU2021121850A (ru) | Лечение офтальмологических патологических состояний ингибиторами ангиопоэтин-подобного белка 7 (angptl7) | |
| RU2023131494A (ru) | Лечение цереброваскулярного заболевания с помощью агентов - белков-гомологов 3 нейрогенного локуса notch (notch3) | |
| JP2024536001A5 (cg-RX-API-DMAC7.html) | ||
| RU2021122161A (ru) | Лечение респираторных нарушений с помощью ингибиторов арахидонат 15-липоксигеназы (alox15) | |
| JP3002115B2 (ja) | ヒト急性および慢性を含む持続性ストレス負荷における細胞内HSP70mRNAの転写異常とその応用(新規ヒト細胞内SHSP70mRNAの転写発現とHSP70mRNA転写異常との応用) | |
| RU2021129890A (ru) | Лечение гипергликемии с помощью ингибиторов члена 5 семейства 39 транспортеров растворенных веществ (slc39a5) | |
| JP2024535110A5 (cg-RX-API-DMAC7.html) | ||
| CN118265529A (zh) | 使用camp应答元件结合蛋白3样3(creb3l3)抑制剂的肝病治疗 |